Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.
Aged
Aged, 80 and over
Biomarkers
/ blood
COVID-19
/ blood
Female
Fibrin Fibrinogen Degradation Products
/ analysis
Humans
Iron
/ blood
Leukocyte Count
Long-Term Care
Lymphocytes
/ pathology
Male
Middle Aged
Monocytes
/ pathology
Platelet Count
Prognosis
Retrospective Studies
SARS-CoV-2
/ physiology
Treatment Outcome
COVID-19
Clinical outcome
D-dimer
Iron
Long-term care facilities
Lymphocyte
Monocyte
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
17 02 2021
17 02 2021
Historique:
received:
19
12
2020
accepted:
08
02
2021
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
25
2
2021
Statut:
epublish
Résumé
The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients' clinical course and outcome. Baseline white blood cells, granulocytes', lymphocytes', and platelets' counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a principal component analysis. Statistical analysis was performed by using R statistical package version 4.0. We identified 3 laboratory patterns of response, renamed as low-risk, intermediate-risk, and high-risk, strongly associated with patients' survival (p < 0.01). D-dimer, iron status, lymphocyte/monocyte count represented the main markers discriminating high- and low-risk groups. Patients belonging to the high-risk group presented a significantly longer time to ferritin decrease (p: 0.047). Iron-to-ferritin-ratio (IFR) significantly segregated recovered and dead patients in the intermediate-risk group (p: 0.012). Our data suggest that a combination of few laboratory parameters, i.e. iron status, D-dimer and lymphocyte/monocyte count at admission and during the hospital stay, can predict clinical progression in COVID-19.
Sections du résumé
BACKGROUND
The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients' clinical course and outcome.
METHODS
Baseline white blood cells, granulocytes', lymphocytes', and platelets' counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a principal component analysis. Statistical analysis was performed by using R statistical package version 4.0.
RESULTS
We identified 3 laboratory patterns of response, renamed as low-risk, intermediate-risk, and high-risk, strongly associated with patients' survival (p < 0.01). D-dimer, iron status, lymphocyte/monocyte count represented the main markers discriminating high- and low-risk groups. Patients belonging to the high-risk group presented a significantly longer time to ferritin decrease (p: 0.047). Iron-to-ferritin-ratio (IFR) significantly segregated recovered and dead patients in the intermediate-risk group (p: 0.012).
CONCLUSIONS
Our data suggest that a combination of few laboratory parameters, i.e. iron status, D-dimer and lymphocyte/monocyte count at admission and during the hospital stay, can predict clinical progression in COVID-19.
Identifiants
pubmed: 33596963
doi: 10.1186/s12967-021-02744-2
pii: 10.1186/s12967-021-02744-2
pmc: PMC7887565
doi:
Substances chimiques
Biomarkers
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Int J Epidemiol. 2021 Jan 23;49(6):1909-1917
pubmed: 33053172
Eur Heart J. 2020 Dec 1;41(45):4332-4345
pubmed: 32330934
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
J Microbiol Immunol Infect. 2020 Jun;53(3):447-453
pubmed: 32303480
Clin Imaging. 2020 Oct;66:35-41
pubmed: 32425338
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Cells. 2020 Jun 26;9(6):
pubmed: 32604861
Science. 2020 Jul 31;369(6503):510-511
pubmed: 32732413
Haematologica. 2020 Dec 17;Online ahead of print:
pubmed: 33327714
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
Front Oncol. 2021 Jan 08;10:599502
pubmed: 33489899
Sci Rep. 2020 Nov 30;10(1):20834
pubmed: 33257703
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Rev Panam Salud Publica. 2020 Jun 01;44:e72
pubmed: 32547616
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
Cell Death Discov. 2020 Nov 25;6:130
pubmed: 33251029
J Microbiol Immunol Infect. 2020 Jun;53(3):444-446
pubmed: 32303483
Nat Rev Mol Cell Biol. 2020 Jan;21(1):4-5
pubmed: 31748716
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Aging Clin Exp Res. 2020 Aug;32(8):1599-1608
pubmed: 32557332
J Med Virol. 2020 Sep;92(9):1676-1680
pubmed: 32330305
Cells. 2020 Jun 20;9(6):
pubmed: 32575749
Int J Mol Sci. 2020 May 25;21(10):
pubmed: 32466282
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Infect. 2020 Aug;81(2):205-212
pubmed: 32579986
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Vasc Med. 2020 Oct;25(5):471-478
pubmed: 32558620
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
J Clin Lab Anal. 2020 Oct;34(10):e23618
pubmed: 33078400
Rev Assoc Med Bras (1992). 2020 Aug;66(8):1152-1156
pubmed: 32935813